{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"82.64","value":"156.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"}],"units":"Participants"}],"title":"Cycle 1 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"78.06","value":"212.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"title":"Cycle 2 Day 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"}],"units":"Participants"}],"description":"Area under the plasma concentration-time curve from Time 0 extrapolated to infinity, calculated as \\[AUCt + Ct/ λz\\]. Ct is the last quantifiable concentration. No AUC extrapolation was performed with unreliable λz. If AUC % extrap is ≥25%, AUCi inf was not reported.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received CC-486 300 mg tablets by mouth (PO) on Days 1-14 of each 21-day treatment cycle and pembrolizumab (PBZ) 200 mg administered as a 30-minute intravenous (IV) infusion on Day 1 of each 21-day cycle until radiologic disease progression (DP), unacceptable toxicity, initiation of a new anticancer therapy, withdrawal of consent, subject refusal, physician decision, or death.","id":"OG000","title":"CC-486 and Pembrolizumab (CC-486 + PBZ)"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"The PK population includes participants with evaluable CC-486 plasma PK profile.","reportingStatus":"POSTED","timeFrame":"Pharmacokinetic (PK) blood samples collected at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6 and 8 hours after CC-486 administration on Cycle 1 Day 1 and Cycle 2 Day 1","title":"Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC∞) of CC-486","type":"SECONDARY","unitOfMeasure":"ng*h/mL"}